QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Pregnancy Prevention Programmes in Pharmacovigilance

Test your understanding of the concepts covered by Pregnancy Prevention Programmes in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most accurate relationship between a PPP and the Risk Management Plan (RMP)?

The PPP replaces the RMP for medicines with reproductive risks The PPP should be an integral, scientifically justified component of the RMP The PPP is managed independently because it is primarily a clinical programme The RMP is relevant only during the marketing authorisation application and not during PPP operation

Question 2 of 10 What is the primary risk-control distinction between pregnancy testing and contraception within a PPP?

Testing prevents conception, whereas contraception detects pregnancy Testing provides evidence about whether pregnancy has occurred, whereas contraception aims to prevent pregnancy during the risk period Testing is a communication tool only, whereas contraception is a pharmacovigilance activity Testing applies only after treatment, whereas contraception applies only before treatment

Question 3 of 10 A company proposes pregnancy testing as the sole control for a highly teratogenic medicine. What is the most appropriate professional response?

Accept it, because a negative test eliminates pregnancy risk for the entire treatment period Accept it, because testing is more objective than counselling or contraception Reject the proposal because testing should be integrated with other measures such as counselling, contraception and clinical review Reject it only if the medicine is dispensed outside a hospital

Question 4 of 10 What is the most mature inspection perspective on a PPP?

Inspectors mainly verify that a patient leaflet exists Inspectors assess whether the integrated system is scientifically justified, implemented, governed, evaluated and improved using objective evidence Inspectors focus exclusively on the number of acknowledgement forms signed Inspectors assess only the clinical decisions of individual prescribers and not the Marketing Authorisation Holder's system

Question 5 of 10 A PPP evaluation shows high distribution of educational materials but continued pregnancy exposure and poor patient understanding. What is the best interpretation?

The programme is effective because distribution is a process indicator The findings suggest implementation of one activity but inadequate evidence of behavioural or clinical effectiveness The exposure data should be ignored because education cannot be evaluated The only appropriate action is to discontinue all additional risk minimisation

Question 6 of 10 Which statement best distinguishes teratogenicity from fetotoxicity?

Teratogenicity concerns structural malformations or permanent developmental abnormalities, whereas fetotoxicity concerns adverse effects after fetal development has progressed Teratogenicity concerns maternal toxicity, whereas fetotoxicity concerns only fertility Teratogenicity refers exclusively to embryo loss, whereas fetotoxicity refers exclusively to congenital malformations There is no meaningful distinction between the two terms in reproductive risk assessment

Question 7 of 10 What is the most appropriate use of educational materials in a PPP?

To replace all verbal counselling with standardised written information To provide unapproved supplementary claims that make the risk more understandable To reinforce counselling and provide consistent, practical information for the intended audience To communicate only to patients, since healthcare professionals already know the requirements

Question 8 of 10 Why does GVP Module XVI not prescribe one standard PPP for every medicinal product?

Because PPPs are voluntary and have no regulatory relevance Because reproductive risks and the effectiveness of possible interventions vary by product and clinical context Because only national authorities can define risk minimisation measures Because PPPs are limited to pregnancy testing and contraception

Question 9 of 10 What is the principal added value of a Patient Alert Card?

It serves as a portable reminder of critical reproductive safety information across healthcare settings It provides a complete substitute for the RMP and educational materials It authorises any healthcare professional to prescribe the medicine It confirms that pregnancy testing is no longer required

Question 10 of 10 Which of the following is a process indicator rather than an outcome indicator?

The rate of pregnancy exposure during treatment Patient understanding of what to do if pregnancy is suspected The proportion of eligible patients who received required counselling Adherence to contraception requirements

Knowledge Assessment: Pregnancy Prevention Programmes in Pharmacovigilance

Cookie Settings